Startups
2014
XENOPAT SLProvide services assisting anticancer drug development and personalized cancer treatment

Advanced Preclinical Services and Personalized Cancer Treatment
Address
Carrer de la Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Spain
Social Media

CERCA ownership

CERCA Center Contact

Other Catalan Public owners

Logo

Status & Deeptech areas

Company Status & Company Deeptech Areas

Current company status

Current company status

DeepTech Area

DeepTech Area

Spinoff information

Company Description

Xenopat is a spin-off company, of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB).

Product description

Advanced Preclinical Services
Xenopat offers researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available. Xenopat offers researchers the OrthoXenoBank®, which is composed of several orthotopic models of different tumor types (orthoxenografts®), characterized at histological and genetic levels, with different sensitivity to diverse chemotherapies.
Personalized Cancer Treatment
Xenopat offers healthcare professionals and patients the most advanced technology in order to select the best treatment in the fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model allows us to test several drugs and find the best therapy for each patient.